[1]
|
Pellicer, A., Lightman, A., Diamond, M.P., Russell, J.B. and De Cherney, A.H. (1987) Outcome of in Vitro Fertilization in Women with Low Response to Ovarian Stimulation. Fertility and Sterility, 47, 812-815. http://dx.doi.org/10.1016/S0015-0282(16)59170-5
|
[2]
|
Wiser, A., Gonen, O., Ghetler, Y., Shavit, T., Berkovitz, A. and Shulman, A. (2010) Addition of Dehydroepiandrosterone (DHEA) for Poor-Responder Patients before and during IVF Treatment Improves the Pregnancy Rate: A Randomized Prospective Study. Human Reproduction (Oxford, England), 25, 2496-500. http://dx.doi.org/10.1093/humrep/deq220
|
[3]
|
Narkwichean, A., Maalouf, W., Campbell, B.K. and Jayaprakasan, K. (2013) Efficacy of Dehydroepiandrosterone to Improve Ovarian Response in Women with Diminished Ovarian Reserve: A Meta-Analysis. Reproductive Biology and Endocrinology: RB & E, 11, 44. http://dx.doi.org/10.1186/1477-7827-11-44
|
[4]
|
Ulug, U., Ben-Shlomo, I., Turan, E., Erden, H.F., Akman, M.A. and Bahceci, M. (2003) Conception Rates Following Assisted Reproduction in Poor Responder Patients: A Retrospective Study in 300 Consecutive Cycles. Reproductive Biomedicine Online, 6, 439-443. http://dx.doi.org/10.1016/S1472-6483(10)62164-5
|
[5]
|
Hofmann, G.E., Toner, J.P., Muasher, S.J. and Jones, G.S. (1989) High-Dose Follicle-Stimulating Hormone (FSH) Ovarian Stimulation in Low-Responder Patients for in Vitro Fertilization. Journal of in Vitro Fertilization and Embryo Transfer: IVF, 6, 285-289. http://dx.doi.org/10.1007/BF01139183
|
[6]
|
Padilla, S.L., Dugan, K., Maruschak, V., Shalika, S. and Smith, R.D. (1996) Use of the Flare-Up Protocol with High Dose Human Follicle Stimulating Hormone and Human Menopausal Gonadotropins for in Vitro Fertilization in Poor Responders. Fertility and Sterility, 65, 796-799. http://dx.doi.org/10.1016/S0015-0282(16)58216-8
|
[7]
|
Hugues, J.N. and Cédrin Durnerin, I.C. (1998) Revisiting Gonadotrophin-Releasing Hormone Agonist Protocols and Management of Poor Ovarian Responses to Gonadotrophins. Human Reproduction Update, 4, 83-101. http://dx.doi.org/10.1093/humupd/4.1.83
|
[8]
|
Surrey, E.S., Bower, J., Hill, D.M., Ramsey, J. and Surrey, M.W. (1998) Clinical and Endocrine Effects of a Microdose GnRH Agonist Flare Regimen Administered to Poor Responders who Are Undergoing in Vitro Fertilization. Fertility and Sterility, 69, 419-424. http://dx.doi.org/10.1016/s0015-0282(97)00575-x
|
[9]
|
Battaglia, C., Salvatori, M., Maxia, N., Petraglia, F., Facchinetti, F. and Volpe, A. (1999) Adjuvant L-Arginine Treatment for in Vitro Fertilization in Poor Responder Patients. Human Reproduction (Oxford, England), 14, 1690-1697. http://dx.doi.org/10.1093/humrep/14.7.1690
|
[10]
|
Franco, J.G., Baruffi, R.L.R., Mauri, A.L., Petersen, C.G., Felipe, V., Cornicelli, J., et al. (2006) GnRH Agonist versus GnRH Antagonist in Poor Ovarian Responders: A Meta-Analysis. Reproductive Biomedicine Online, 13, 618-627. http://dx.doi.org/10.1016/S1472-6483(10)60651-7
|
[11]
|
Frattarelli, J.L., McWilliams, G.D.E., Hill, M.J., Miller, K.A. and Scott, R.T. (2008) Low-Dose Aspirin Use Does Not Improve in Vitro Fertilization Outcomes in Poor Responders. Fertility and Sterility, 89, 1113-1117. http://dx.doi.org/10.1016/j.fertnstert.2007.05.007
|
[12]
|
Garcia-Velasco, J.A., Moreno, L., Pacheco, A., Guillén, A., Duque, L., Requena, A., et al. (2005) The Aromatase Inhibitor Letrozole Increases the Concentration of Intraovarian Androgens and Improves in Vitro Fertilization Outcome in Low Responder Patients: A Pilot Study. Fertility and Sterility, 84, 82-87. http://dx.doi.org/10.1016/j.fertnstert.2005.01.117
|
[13]
|
Hill, M.J., McWilliams, G.D.E., Miller, K.A., Scott, R.T. and Frattarelli, J.L. (2009) A Luteal Estradiol Protocol for Anticipated Poor-Responder Patients May Improve Delivery Rates. Fertility and Sterility, 91, 739-743. http://dx.doi.org/10.1016/j.fertnstert.2007.12.073
|
[14]
|
Schoolcraft, W.B., Surrey, E.S., Minjarez, D.A., Stevens, J.M. and Gardner, D.K. (2008) Management of Poor Responders: Can Outcomes Be Improved with a Novel Gonadotropin-Releasing Hormone Antagonist/Letrozole Protocol? Fertility and Sterility, 89, 151-156. http://dx.doi.org/10.1016/j.fertnstert.2007.02.013
|
[15]
|
Lehert, P., Kolibianakis, E.M., Venetis, C.A., Schertz, J., Saunders, H., Arriagada, P., et al. (2014) Recombinant Human Follicle-Stimulating Hormone (r-hFSH) Plus Recombinant Luteinizing Hormone versus r-hFSH Alone for Ovarian Stimulation during Assisted Reproductive Technology: Systematic Review and Meta-Analysis. Reproductive Biology and Endocrinology: RB & E, 12, 17. http://dx.doi.org/10.1186/1477-7827-12-17
|
[16]
|
Pandian, Z., McTavish, A.R., Aucott, L., Hamilton, M.P. and Bhattacharya, S. (2010) Interventions for “Poor Responders” to Controlled Ovarian Hyper Stimulation (COH) in in Vitro Fertilization (IVF). Cochrane Database of Systematic Reviews, No. 1, Article No. CD004379. http://dx.doi.org/10.1002/14651858.cd004379.pub3
|
[17]
|
Casson, P.R., Lindsay, M.S., Pisarska, M.D., Carson, S.A. and Buster, J.E. (2000) Dehydroepiandrosterone Supplementation Augments Ovarian Stimulation in Poor Responders: A Case Series. Human Reproduction (Oxford, England), 15, 2129-2132. http://dx.doi.org/10.1093/humrep/15.10.2129
|
[18]
|
Burger, H.G. (2002) Androgen Production in Women. Fertility and Sterility, 77, S3-S55. http://dx.doi.org/10.1016/S0015-0282(02)02985-0
|
[19]
|
Ben-Chetrit, A., Gotlieb, L., Wong, P.Y. and Casper, R.F. (1996) Ovarian Response to Recombinant Human Follicle-Stimulating Hormone in Luteinizing Hormone-Depleted Women: Examination of the Two Cell, Two Gonadotropin Theory. Fertility and Sterility, 65, 711-717. http://dx.doi.org/10.1016/S0015-0282(16)58201-6
|
[20]
|
McNatty, K.P., Makris, A., Reinhold, V.N., De Grazia, C., Osathanondh, R. and Ryan, K.J. (1979) Metabolism of Androstenedione by Human Ovarian Tissues in Vitro with Particular Reference to Reductase and Aromatase Activity. Steroids, 34, 429-443. http://dx.doi.org/10.1016/0039-128X(79)90104-1
|
[21]
|
Orentreich, N., Brind, J.L., Rizer, R.L. and Vogelman, J.H. (1984) Age Changes and Sex Differences in Serum Dehydroepiandrosterone Sulfate Concentrations throughout Adulthood. The Journal of Clinical Endocrinology and Metabolism, 59, 551-555. http://dx.doi.org/10.1210/jcem-59-3-551
|
[22]
|
Morales, A.J., Nolan, J.J., Nelson, J.C. and Yen, S.S. (1994) Effects of Replacement Dose of Dehydroepiandrosterone in Men and Women of Advancing Age. The Journal of Clinical Endocrinology and Metabolism, 78, 1360-1367. http://dx.doi.org/10.1210/jcem.78.6.7515387
|
[23]
|
Barad, D. and Gleicher, N. (2006) Effect of Dehydroepiandrosterone on Oocyte and Embryo Yields, Embryo Grade and Cell Number in IVF. Human Reproduction (Oxford, England), 21, 2845-2849. http://dx.doi.org/10.1093/humrep/del254
|
[24]
|
Mahajan, D.K. (1988) Polycystic Ovarian Disease: Animal Models. Endocrinology and Metabolism Clinics of North America, 17, 705-732.
|
[25]
|
Luchetti, C.G., Solano, M.E., Sander, V., Arcos, M.L.B., Gonzalez, C., Di Girolamo, G., et al. (2004) Effects of Dehydroepiandrosterone on Ovarian Cystogenesis and Immune Function. Journal of Reproductive Immunology, 64, 59-74. http://dx.doi.org/10.1016/j.jri.2004.04.002
|
[26]
|
Billig, H., Furuta, I. and Hsueh, A.J. (1993) Estrogens Inhibit and Androgens Enhance Ovarian Granulosa Cell Apoptosis. Endocrinology, 133, 2204-2212.
|
[27]
|
Kaipia, A. and Hsueh, A.J. (1997) Regulation of Ovarian Follicle Atresia. Annual Review of Physiology, 59, 349-363. http://dx.doi.org/10.1146/annurev.physiol.59.1.349
|
[28]
|
Hyman, J.H., Margalioth, E.J., Rabinowitz, R., Tsafrir, A., Gal, M., Alerhand, S., et al. (2013) DHEA Supplementation May Improve IVF Outcome in Poor Responders: A Proposed Mechanism. European Journal of Obstetrics, Gynecology and Reproductive Biology, 168, 49-53. http://dx.doi.org/10.1016/j.ejogrb.2012.12.017
|
[29]
|
Jirge, P.R., Chougule, S.M., Gavali, V.G. and Bhomkar, D.A. (2014) Impact of Dehydroepiandrosterone on Clinical Outcome in Poor Responders: A Pilot Study in Women Undergoing in Vitro Fertilization, Using Bologna Criteria. Journal of Human Reproductive Sciences, 7, 175-180. http://dx.doi.org/10.4103/0974-1208.142477
|
[30]
|
Barad, D., Brill, H. and Gleicher, N. (2007) Update on the Use of Dehydroepiandrosterone Supplementation among Women with Diminished Ovarian Function. Journal of Assisted Reproduction and Genetics, 24, 629-634. http://dx.doi.org/10.1007/s10815-007-9178-x
|
[31]
|
Yeung, T.W.Y., Chai, J., Li, R.H.W., Lee, V.C.Y., Ho, P.C. and Ng, E.H.Y. (2014) A Randomized, Controlled, Pilot Trial on the Effect of Dehydroepiandrosterone on Ovarian Response Markers, Ovarian Response, and in Vitro Fertilization Outcomes in Poor Responders. Fertility and Sterility, 102, 108-115.e1. http://dx.doi.org/10.1016/j.fertnstert.2014.03.044
|
[32]
|
Vlahos, N., Papalouka, M., Triantafyllidou, O., Vlachos, A., Vakas, P., Grimbizis, G., et al. (2015) Dehydroepiandrosterone Administration before IVF in Poor Responders: A Prospective Cohort Study. Reproductive Biomedicine Online, 30, 191-196.
|
[33]
|
Sunkara, S.K., Pundir, J. and Khalaf, Y. (2011) Effect of Androgen Supplementation or Modulation on Ovarian Stimulation Outcome in Poor Responders: A Meta-Analysis. Reproductive Biomedicine Online, 22, 545-555. http://dx.doi.org/10.1016/j.rbmo.2011.01.015
|
[34]
|
Leong, M. and Patrizio, P. (2014) Poor Responders: How to Define, Diagnose and Treate?
|
[35]
|
Ferraretti, A.P., La Marca, A., Fauser, B.C.J.M., Tarlatzis, B., Nargund, G., Gianaroli, L., et al. (2011) ESHRE Consensus on the Definition of “Poor Response” to Ovarian Stimulation for in Vitro Fertilization: The Bologna Criteria. Human Reproduction (Oxford, England), 26, 1616-1624. http://dx.doi.org/10.1093/humrep/der092
|
[36]
|
Sunkara, S.K., Coomarasamy, A., Faris, R., Braude, P. and Khalaf, Y. (2014) Long Gonadotropin-Releasing Hormone Agonist versus Short Agonist versus Antagonist Regimens in Poor Responders Undergoing in Vitro Fertilization: A Randomized Controlled Trial. Fertility and Sterility, 101, 147-153. http://dx.doi.org/10.1016/j.fertnstert.2013.09.035
|
[37]
|
Poli, E., Manfé, S., Capuzzo, D., Gava, S., Viganò, F., Coronella, M.L., et al. (2014) DHEA Pre-Treated Patients, Poor Responders to a First IVF (ICSI) Cycle: Clinical Results. Clinical and Experimental Obstetrics & Gynecology, 41, 5-9.
|
[38]
|
Singh, N., Zangmo, R., Kumar, S., Roy, K.K., Sharma, J.B., Malhotra, N., et al. (2013) A Prospective Study on Role of Dehydroepiandrosterone (DHEA) on Improving the Ovarian Reserve Markers in Infertile Patients with Poor Ovarian Reserve. Gynecological Endocrinology: The Official Journal of the International Society of Gynecological Endocrinology, 29, 989-992. http://dx.doi.org/10.3109/09513590.2013.824957
|
[39]
|
Kara, M., Aydin, T., Aran, T., Turktekin, N. and Ozdemir, B. (2014) Does Dehydroepiandrosterone Supplementation really Affect IVF-ICSI Outcome in Women with Poor Ovarian Reserve? European Journal of Obstetrics, Gynecology and Reproductive Biology, 173, 63-65. http://dx.doi.org/10.1016/j.ejogrb.2013.11.008
|
[40]
|
Li, J., Yuan, H., Chen, Y., Wu, H., Wu, H. and Li, L. (2015) A Meta-Analysis of dehydroepiandrosterone Supplementation among Women with Diminished Ovarian Reserve Undergoing in Vitro Fertilization or Intracytoplasmic Sperm Injection. International Journal of Gynecology & Obstetrics, 131, 240-245.
|
[41]
|
Gleicher, N., Ryan, E., Weghofer, A., Blanco-Mejia, S. and Barad, D.H. (2009) Miscarriage Rates after Dehydroepiandrosterone (DHEA) Supplementation in Women with Diminished Ovarian Reserve: A Case Control Study. Reproductive Biology and Endocrinology, 7, 108. http://dx.doi.org/10.1186/1477-7827-7-108
|
[42]
|
Gleicher, N., Weghofer, A. and Barad, D.H. (2010) Dehydroepiandrosterone (DHEA) Reduces Embryo Aneuploidy: Direct Evidence from Preimplantation Genetic Screening (PGS). Reproductive Biology and Endocrinology, 8, 140. http://dx.doi.org/10.1186/1477-7827-8-140
|
[43]
|
Kroboth, P.D., Salek, F.S., Pittenger, A.L., Fabian, T.J. and Frye, R.F. (1999) DHEA and DHEA-S: A Review. The Journal of Clinical Pharmacology, 39, 327-348. http://dx.doi.org/10.1177/00912709922007903
|
[44]
|
Panjari, M., Bell, R.J., Jane, F., Adams, J., Morrow, C. and Davis, S.R. (2009) The Safety of 52 Weeks of Oral DHEA Therapy for Postmenopausal Women. Maturitas, 63, 240-245. http://dx.doi.org/10.1016/j.maturitas.2009.03.020
|